Kristopher Zepeda, PharmD, BCOP, MBA

Rhiannon Dorris, PharmD, BCOP, BCPS was recently on a panel to discuss ‘Immunotherapy toxicities in CLL, myeloma, lymphoma’ as part of the hematological malignancies update at MLS (Master Lecture Series) Nashville: Review of 2024 ASCO. #TennesseeOncology #Community #Oncology #Cancer #ASCO

89

4 Comments

Are you conducting groundbreaking research on Cutaneous Lupus? ➡️ Share your insights at #LUPUS2025! We're looking for innovative studies exploring the pathogenesis, diagnosis, and treatment of Cutaneous Lupus. Join global experts and contribute to advancing our understanding of this complex condition. 🔗 Submit your abstract by 5 November: https://bit.ly/3WTYC4A #SLE #Rheum #Rheumatology #Autoimmunity

11

Navigating the complexities of multiple myeloma (MM) treatment can be daunting in today’s rapidly evolving oncology landscape. Kirollos Hanna, PharmD, BCPS, BCOP, FACCC (Minnesota Oncology), tackled these challenges head-on in a recent NCODA webinar providing insights into the latest advancements and strategies for effectively implementing new therapies in MM. View the complete presentation at the link below: https://lnkd.in/eBm7bDJw

46

Dive into our newest Peer Exchange series, where expert panel including Craig Beavers, PharmD, FACC, FAHA,FCCP,BCCP,CACP; Dave Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS; Joseph Saseen, PharmD, MNLA, FCCP, FAHA, BCPS, BCACP, CLS; Kate Phillips Cabral, PharmD, BCCP, FACC, FCCP; and Kelsey Norman, PharmD, BCCP, BCACP, BCPS, discussed the challenges of achieving LDL cholesterol targets. Enhance your understanding of statin therapy optimization and uncover the barriers to advancing heart health treatment. Start watching the ongoing episodes today: https://bit.ly/49Te1GD.

45

1 Comment

Worth a read:

5

Biosimilars might be the life raft you need! 🆘 Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, breaks down innovative treatments that can deliver high-quality cancer care WITHOUT breaking the bank. She discusses: *US biologics market growing 12.5% annually over the past 5 years *Biologics projected to be 55% of the top 100 medications used in the US by 2026! *Areas she focuses on to promote biosimilars in her practice  *Adoption of clinical management programs  *PBM contract negotiations To read the full article:  https://lnkd.in/ePiXXK-q

2

ASCO24, that's a wrap! - Thomas LeBlanc (Duke Cancer Institute) American Society of Clinical Oncology (ASCO) #oncodaily #oncology #cancer #ASCO2024 #ASCO24

16

🎥 Dive into the latest Norton Infectious Diseases Institute Grand Rounds with Jamison Montes de Oca, PharmD, and Sarah Moore, PharmD, BCIDP! They unpack updated guidance on treating recurrent C. diff infections, covering innovative approaches like FMT and the potential use of tapered oral vancomycin. Watch now for valuable insights: https://lnkd.in/ejSUDaJQ #InfectiousDiseases #CdiffTreatment #PharmacyUpdates #FMT #HealthcareEducation

5

In oncology, triage is especially critical to patient care. Learn how care teams are leveraging Operator and Triage Pathways to standardize quality processes for both clinical and non-clinical staff, ultimately driving better patient care.

7

#ICYMI: #ComboMATCH Treatment Trial A3, led by Alliance researcher Geoffrey I Shapiro, MD, PhD, of Dana-Farber Cancer Institute, is evaluating the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. To learn more about this ComboMATCH trial, visit https://bit.ly/cmatch-A3 #PrecisionMedicine #NCI #NCTN

1

#ADC #antibodydrugconjugate New Phase 3 data evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, in previously treated locally recurrent or metastatic triple-negative breast cancer First presentation of Phase 2b three-year follow-up data evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk stage III/IV melanoma following complete resection

1

Linda Rogers, MD, discusses a study regarding the use of an investigational oral Bruton's tyrosine kinase inhibitor as treatment for patients with poorly controlled asthma. Linda Rogers #AsthmaTreatment #ClinicalResearch #MedicalInnovation #Pulmonology #AsthmaManagement #BrutonsTyrosineKinase https://lnkd.in/eyKYqm8R

17

Please see the attached press release for powerful data regarding our moderate-severe atopic dermatitis candidate. #eczema #dermatology

2

🎧 #ICYMI: When Lorece Shaw, PharmD (Director, Prior Authorization) joined us for episode 17 of Astonishing Healthcare, she shared a personal story about a situation where she was prescribed twice the recommended dose of a #medication. Thankfully, she was able to catch the mistake due to her experience and speak with the dispensing #pharmacist, but we all know that the healthcare system can be challenging to navigate, even for experienced consumers. In cases like these, #priorauthorization can help as well! You can listen to the entire episode here: https://okt.to/cD4ibx

19

1 Comment